. Disodium cromoglycate can also inhibilt the immediate-type bronchial reaction a,fter challenge with antigen, but as a single dose it does not consistently alter the late component in dual bronchial reactions (Pepys et al., 1968) . One of its limitations is that since it is poorly absorbed by the gut it is inactive when taken by month. A new compound, AH 7725, has been shown to have similar properties to -those of disodium cromoglycate both in laboratory models (Assem, 1973; Fullarton et al., 1973) and when given by inhalation in experimental asthma (Gayrard, 1974) . This new drug has the additional property of being relatively well absorbed from the gut and can -therefore be taken by month.
We here report experiments itesting the protective effect of AH 7725 given by mouth to asthmatic patientts subjected to bronchial haMlenge with antigen.
Materials and Methods
The structural formula of AH 7725 is shown in the fig. Blood levels after the administration of single doses by mouth to normal volunteers have been measured by Woodings (1974) . After doses of 200 to 500 mg in solution peak levels ranging from 2-7 ,ug/ml of plasma were reached in one and a half to two and a half hours.
BRONCHIAL TESTING PROCEDURE
Tests were carried out by the closed-circuit method (Herxheimer, 1951; McAllen, 1961) were allergic to grass pollen and one was allergic to Dermatophagoides pteronyssinus (house-dust mite).
TRIAL DESIGN
After the preliminary challenge tests, in which it had been established that a reduotion in ventilatory function of 20 tto 300% could be provoked within 15 minutes of the test, the patients were given three further itests at seven-day intervals in the following order. (a) The dosage of antigen which provoked the required fall in ventilatory function was confirmed. (b) Pretreatment with a dose of 500 mg AH 7725 in 30 ml of water was given by mouth to the patient on an empty stomach two hours before the challenge test. The challenge was repeated with the same dose of antigen as in test a. (c) Pretreatment with a placebo of identical taste and appearance was given two hours before the test. Challenge was again repeated with the same dose of antigen. The trial was carried out as a single-blind procedure but the patients were under the impression that two drugs were being compared.
of predictable degree can be induced by this method, and the amount of reduction in ventilatory function from a given dose of antigen is reproducible (McAllen et al., 1970) . Testing is started with a low dose of antigen, and only one test is done on any one day in order to record any reaction coming on after several hours. Tests are repeated at not less than weekly intervals in order to prevent unwanted local desensitization by the testing procedure a). The dosage of antigen is increased by 100 ,to 200% at each session until 'the required asthmatic response is obtained. For the purpose of this investigation a reduction in forced expiratory volume in one second (FEV,) of 20 to 30 % was thought necessary, so that the drug could be tested in as severe an asthmatic attack as we considered ethical to induce and which would be of no grea't discomfort to the patient.
The antigens used were grass pollen and house-dust mite extracts. The tests were carried out on patients who already had asthma due to these antigens and were done in winter months when grass pollen is absent from the air.
Results
The results set out below refer only to the immediate response to bronchial challenge, since the late responses were unchanged by the drug ( In test a the mean fall in FEV, was 279% of the control level (range 21 to 34%) and in FVC 16-2% (range 5 to 33%). In test b the mean fall in FEV, was 79% (range 0 to 15%) and in FVC 3 2% (range 0 to 9%). No (Assem, 1973; Assem and McAllen, 1973 b) . It is, however, exceptional in being active when given by mouth. So far as we know this is the first report on a d1rug for the prophylaxis of asthma which is active when given by mouth.
Our results encourage the hope tihat AH 7725 has a potential in future clinical practice. Many asthmatic patients would prefer to take a prophylactic drug by mouth rathecr ,than by inhalation, and this new compound may be of particular value in very young children with asthma and in those adults who cannot master the necessary inhalation technique for using disodium cromoglycate. The possible use of AH 7725 in allergic conditions which require systemic treatment awaits investigation.
Patienits with left atrial myxoma characteristically present with a history of progressive shortness of breath, often punctuated by syncopal attacks, and physical signs of miitral valve obstruction (Goodwin, 1963; Greenwood, 1968; Harvey, 1968) . Predominant or "pure" mitral regurgitation due to left atrial myxoma has been reported but is uncommon (Cohen et al., 1963; Penny et al., 1967; Wittenstein et al., 1959) . This report describes a patient with a calcified left atrial myxoma who presented with sudden severe mitral regurgitation due to ruptured chordae tendineae.
Case Report A 44-year-old machinist, previously well and active, abruptly developed dyspnoea and orthopnoea during the first week of December 1972. He was admitted to his local hospital where he was found to have cardiac enlargement, pulmonary oedema, and bilateral pleural effusion. The electrocardiogram showed sinus rhythm with evidence of left atrial enlargement. A heart murmur had been heard one year earlier, but he was told "not to worry" about his heart. There was no history of rheumatic fever, chest pain, calf tendemess or swelling, or fever or chills. Digitalis (digoxin 0-25 mg/day) and a diuretic (Lasix Cardiology Section, Medical Service, Eastern Maine Medical Center, Bangor, Maine, 0441, U.S.A. JOE R. WISE, juN., M.D., Attending Physician 40 mg/day) were given but dyspnoea, orthopnoea, and fatigue persisted, atrial fibrillation developed, and he was referred for consultation.
On examination he was very thin and dyspnoeic at rest. Atrial fibrillation was present, the blood pressure was 110/60 mm Hg, there were no signs of peripheral embolism, and the optic fundi were normal. The carotid pulse was small and rapid, the venous pressure was raised, and there was prominent systolic pulsation of the neck veins. The apex beat was in the mid-clavicular line and there was a prominent, diffuse systolic pulsation in the third to fifth interspaces midway between the sternum and the apex. The pulmonary valve closure sound was increased and the aortic component normal. A loud first heart sound was followed by a grade III/VI regurgitant murmur heard best at the apex. There was a prominent early third heart sound and a faint mid-diastolic apical murmur. The lungs were clear. The liver was palpable 2 cm below the right costal margin in the midclavicular line. Chest x-ray examination showed enlargement of the left ventricle and left atrium, pulmonary venous congestion, and costophrenic septal (Kerley's B) lines.
After some initial improvement progressive dyspnoea and orthopnoea had recurred after three months. Cinefluoroscopy showed a mobile, calcified mass in the left atrium which appeared to enter and partially obstruct the mitral valve orifice during diastole. Pulmonary capillary wedge pressure and right heart pressure were raised (see table) and there was evidence of mitral and tricuspid regurgitation. At operation the left atrium was found to contain a large, calcified myxoma (see fig.) attached by a 1-cm pedicle to the atrial septum just below the limbus of the fossa ovalis. The mitral valve leaflets were thickened and damaged and many chordae tendineae were ruptured. 
